Episode 18: A Between the Biotech Waves conversation with Ram Aiyer, CEO of RNA base editing company Korro Bio
Between the Biotech Waves
00:00
Using a Small Molecule Target in Oncology
With our first target, with a single edit, we have now been able to show that we can have a meaningful increase in a certain transcription factor. And it's almost like mutagenesis studies that you can do in log to actually help a certain phenotype. You can now do it in humans. So these are just two examples, two short-term goals. But if you think about the applications and where you can really use it, you can get very creative and use pharmacology as well as genetics to bring together applications that have never been done before. That was the other exciting part when I spoke to Andrew and you in the context of coming onto coral.
Transcript
Play full episode
